Epratuzumab clinical trials
How each study uses epratuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 11
UCB Pharma (12) · Nantes University Hospital (2) · Alliance for Clinical Trials in Oncology (2) · Gilead Sciences (2) · Jonsson Comprehensive Cancer Center (2) · Charite University, Berlin, Germany (1) · Children's Oncology Group (1) · SWOG Cancer Research Network (1)
Often tested with
Tested in the same studies.
Clofarabine (1) · Cytarabine (1) · Yttrium Y-90 epratuzumab tetraxetan (1)
Studies
Open first, then newest update. How each study uses epratuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 27
- Multi-centric StudyCompletedPhase 2Nantes University HospitalNCT01219816Written as EpratuzumabHow we know
- International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010CompletedPhase 3Charite University, Berlin, GermanyNCT01802814Written as SR-A + EpratuzumabHow we know
- Study of Epratuzumab (hLL2) in Patients With Waldenstrom's MacroglobulinemiaTerminatedPhase 2Gilead SciencesNCT00113802Written as Epratuzumab (hLL2- anti-CD22 humanized antibody)How we know
- Study of 90Y-hLL2 to Treat Non-Hodgkin's LymphomaTerminatedPhase 1Gilead SciencesNCT00054834Written as hLL2 (epratuzumab)How we know
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)CompletedPhase 3UCB PharmaNCT01261793Written as EpratuzumabHow we know
- Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00301821Written as epratuzumabHow we know
- Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus ErythematosusCompletedPhase 3UCB PharmaNCT01408576Written as EpratuzumabHow we know
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus ErythematosusCompletedPhase 3UCB PharmaNCT01262365Written as EpratuzumabHow we know
- Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)CompletedPhase 1/2Children's Oncology GroupNCT00098839Written as epratuzumabHow we know
- S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 2SWOG Cancer Research NetworkNCT00945815Written as epratuzumabHow we know
- Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00553501Written as epratuzumabHow we know
- Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) SubjectsCompletedPhase 2UCB PharmaNCT01534403Written as EpratuzumabHow we know
- Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the BloodCompletedPhase 1UCB Biopharma S.P.R.L.NCT02306629Written as Epratuzumab scHow we know
- Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+Status unknownPhase 1/2Nantes University HospitalNCT01354457Written as Epratuzumab and 90Y-EpratuzumabHow we know
- Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)TerminatedPhase 2M.D. Anderson Cancer CenterNCT00941928Written as EpratuzumabHow we know
- Study of Epratuzumab in Systemic Lupus ErythematosusWithdrawnPhase 3UCB PharmaNCT00382837Written as EpratuzumabHow we know
- Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)CompletedPhase 1/2UCB PharmaNCT01449071Written as Epratuzumab 400 mgHow we know
- Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownPhase 2Jonsson Comprehensive Cancer CenterNCT00042913Written as epratuzumabHow we know
- Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownPhase 3Jonsson Comprehensive Cancer CenterNCT00022685Written as epratuzumabHow we know
- Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active DiseaseCompletedPhase 2UCB PharmaNCT00660881Written as EpratuzumabHow we know
Codes
What other systems call epratuzumab · ClinicalTrials.gg INT004428
- MeSH (NLM) C448700epratuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3062P60MH9EPRATUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3730737epratuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1887EpratuzumabOne source FDA
- DrugBank DB04958One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C448700 | epratuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3062P60MH9 | EPRATUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3730737 | epratuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1887 | Epratuzumab | One source FDA |
| DrugBank | DB04958 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.